Abstract
Background Antenatal corticosteroids are given primarily to induce fetal lung maturation but results from meta-analyses of randomized controlled trials have not shown mortality or pulmonary benefits for extremely preterm infants although these are the infants most at risk of mortality and pulmonary disease. Objective We sought to determine if exposure to antenatal corticosteroids is associated with a lower rate of death and pulmonary morbidities by 36 weeks’ postmenstrual age. Study Design Prospectively collected data on 11,022 infants 22 0/7 to 28 6/7 weeks’ gestational age with a birthweight of ≥401 g born from Jan. 1, 2006, through Dec. 31, 2014, were analyzed. The rate of death and the rate of physiologic bronchopulmonary dysplasia by 36 weeks’ postmenstrual age were analyzed by level of exposure to antenatal corticosteroids using models adjusted for maternal variables, infant variables, center, and epoch. Results Infants exposed to any antenatal corticosteroids had a lower rate of death (2193/9670 [22.7%]) compared to infants without exposure (540/1302 [41.5%]) (adjusted relative risk, 0.71; 95% confidence interval, 0.65–0.76; P
Author supplied keywords
- antenatal corticosteroids
- bronchopulmonary dysplasia
- infant
- intracranial hemorrhage
- mechanical ventilation
- morbidity
- mortality
- necrotizing enterocolitis
- neonatal
- newborn
- patent ductus arteriosus
- periventricular leukomalacia
- pneumothorax
- preterm
- pulmonary
- pulmonary hemorrhage
- respiratory distress syndrome
- respiratory support
- sepsis
- surfactant
Cite
CITATION STYLE
Travers, C. P., Carlo, W. A., McDonald, S. A., Das, A., Bell, E. F., Ambalavanan, N., … Archer, S. W. (2018). Mortality and pulmonary outcomes of extremely preterm infants exposed to antenatal corticosteroids. American Journal of Obstetrics and Gynecology, 218(1), 130.e1-130.e13. https://doi.org/10.1016/j.ajog.2017.11.554
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.